Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China.

Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China.
复制标题

重庆农村人群幽门螺杆菌抗生素耐药性及CYP2C19基因多态性分布的多中心研究

DOI:
10.1155/2016/8547686
复制
发表时间:
2016
影响因子:
2
通讯作者:
Wu XL
Wu XL
中科院分区:
医学4区
文献类型:
--
作者:
Han R;Lu H;Jiang MW;Tan KW;Peng Z;Hu JL;Fang DC;Lan CH;Wu XL

文献摘要

被引文献

相似文献

本研究旨在了解H.中国重庆农村人群CYP 2C 19基因多态性分布214株和111株H. pylori分别从农村和城市患者中分离。农村患者分离的菌株对甲硝唑、克拉霉素和左氧氟沙星的耐药率分别为99.53%、20.09%和23.36%,而城市患者的耐药率分别为82.88%、19.82%和24.32%。农村患者多重耐药率由45岁以下的28.26%上升到45岁以上的41.80%。农村、农村、农村H. pylori菌株分为快代谢型、中代谢型和慢代谢型。H. pylori感染与CYP 2C 19基因多态性的关系H.中国重庆农村患者中甲硝唑、克拉霉素和左氧氟沙星耐药的幽门螺杆菌菌株在这方面的治疗选择应根据当地的易感性模式。推荐阿莫西林、庆大霉素和呋喃唑酮作为一线经验性方案。
This study was to investigate the antibiotic resistance profile of H. pylori and the distribution of CYP2C19 gene polymorphism in rural population of Chongqing, China. 214 and 111 strains of H. pylori were isolated from rural and urban patients, respectively. 99.53%, 20.09%, and 23.36% of the isolates in rural patients were found to be resistant to metronidazole, clarithromycin, and levofloxacin, while the resistant rate in urban patients was 82.88%, 19.82%, and 24.32%. The multiple antibiotic resistance percentage significantly increased from 28.26% (below 45 years) to 41.80% (above 45 years) in rural patients. Up to 44.39%, 45.79%, and 9.81% of rural patients from whom H. pylori was isolated were found to be extensive metabolizers, intermediate metabolizers, and poor metabolizers. No correlation was observed between antibiotic resistance profile of H. pylori and genetic polymorphism of CYP2C19 among rural population. There was a high prevalence of H. pylori strains resistant to metronidazole, clarithromycin, and levofloxacin in rural patients in Chongqing, China. The choice of therapy in this area should be based on local susceptibility patterns. Amoxicillin, gentamicin, and furazolidone are recommended as the first-line empiric regimen.